Pavlinac, P.B.; Rogawski McQuade, E.T.; Platts-Mills, J.A.; Kotloff, K.L.; Deal, C.; Giersing, B.K.; Isbrucker, R.A.; Kang, G.; Ma, L.-F.; MacLennan, C.A.;
et al. Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group. Vaccines 2022, 10, 489.
https://doi.org/10.3390/vaccines10040489
AMA Style
Pavlinac PB, Rogawski McQuade ET, Platts-Mills JA, Kotloff KL, Deal C, Giersing BK, Isbrucker RA, Kang G, Ma L-F, MacLennan CA,
et al. Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group. Vaccines. 2022; 10(4):489.
https://doi.org/10.3390/vaccines10040489
Chicago/Turabian Style
Pavlinac, Patricia B., Elizabeth T. Rogawski McQuade, James A. Platts-Mills, Karen L. Kotloff, Carolyn Deal, Birgitte K. Giersing, Richard A. Isbrucker, Gagandeep Kang, Lyou-Fu Ma, Calman A. MacLennan,
and et al. 2022. "Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group" Vaccines 10, no. 4: 489.
https://doi.org/10.3390/vaccines10040489
APA Style
Pavlinac, P. B., Rogawski McQuade, E. T., Platts-Mills, J. A., Kotloff, K. L., Deal, C., Giersing, B. K., Isbrucker, R. A., Kang, G., Ma, L.-F., MacLennan, C. A., Patriarca, P., Steele, D., & Vannice, K. S.
(2022). Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group. Vaccines, 10(4), 489.
https://doi.org/10.3390/vaccines10040489
